Skip to main content

The Journal Gazette

Tuesday, February 12, 2013 4:42 pm

Avon, Facebook, Apple are market movers

The Associated Press

Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and Nasdaq Stock Market:


Avon Products Inc., up $3.51 to $20.79

Fourth-quarter earnings were far better than anyone expected, turning the long-suffering cosmetics company into the biggest gainer on the S&P 500.

Masco Corp., up $2.22 to $20.01

Shares jumped to levels not seen in about five years as the home improvement and building products company rides a wave of recovery in the real estate market.

Cubic Corp., down $3.40 to $45

Transportation-related operating income tumbled 26 percent in the first quarter, defense profits plunged 80 percent, and Benchmark analyst Josephine Millward stripped the company of its "Buy" rating.

Dun & Bradstreet Corp., down $6.60 to $78.68

The credit and business data company posted a 7 percent decline in revenue, deflating the hopes of investors that latched on to what they saw as a company with tremendous growth potential.


StemCells Inc., up 35 cents to $1.99

A small company and a small sample of patients, but StemCells reported that two of three patients with "complete" spinal cord injury at chest level, which means they had no nerve function or feeling below the area that was injured, experienced greater sensory function a year after treatment.

Facebook Inc., down 89 cents to $27.37

A Bernstein Research analyst downgraded the social network company. He said prices for ads were "anemic" in the fourth quarter and while much of the upside to the stock price has been priced in, downside risks loom.

Amyris, Inc., down 31 cents to $3.52

Even with the biofuel company burning through cash, Raymond James analysts note that the stock this year is soaring, up nearly 23 percent at the close Monday. That's too rich for analyst Pavel Molchanov, who downgraded the stock.

Apple Inc., down $12.03 to $467.90

CEO Tim Cook took the stage at the Goldman Sachs investor conference and didn't seem to say what investors, who have sent company shares down sharply, wanted to hear.